Pfizer 将来の成長

Future 基準チェック /26

Pfizer利益と収益がそれぞれ年間16.8%と0.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に17% 16.9%なると予測されています。

主要情報

16.8%

収益成長率

16.9%

EPS成長率

Pharmaceuticals 収益成長	19.6%
収益成長率	0.8%
将来の株主資本利益率	17.0%
アナリストカバレッジ	Good
最終更新日	20 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BVL:PFE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	63,589	12,291	17,010	19,962	21
12/31/2025	62,934	11,329	16,391	18,444	23
12/31/2024	62,598	9,214	8,604	16,073	23
9/29/2024	59,375	4,274	8,227	11,263	N/A
6/30/2024	55,166	-2,593	4,810	8,005	N/A
3/31/2024	54,889	-288	5,106	8,578	N/A
12/31/2023	58,496	2,134	4,793	8,700	N/A
10/1/2023	69,274	10,469	8,178	12,042	N/A
7/2/2023	78,420	21,494	10,665	14,560	N/A
4/2/2023	93,154	29,035	20,206	23,938	N/A
12/31/2022	100,330	31,366	26,031	29,267	N/A
10/2/2022	99,878	29,953	23,362	26,599	N/A
7/3/2022	101,275	29,481	28,440	31,454	N/A
4/3/2022	92,433	25,410	31,783	34,583	N/A
12/31/2021	81,288	22,413	29,869	32,580	N/A
10/3/2021	68,877	19,485	29,769	32,291	N/A
7/4/2021	55,119	12,236	21,141	23,552	N/A
4/4/2021	46,084	9,032	13,477	15,808	N/A
12/31/2020	41,651	6,630	12,177	14,403	N/A
9/27/2020	32,334	212	10,512	12,547	N/A
6/28/2020	34,737	6,977	12,777	14,967	N/A
3/29/2020	38,137	9,427	11,702	14,023	N/A
12/31/2019	40,905	10,707	10,542	12,588	N/A
9/29/2019	53,039	16,211	10,897	13,557	N/A
6/30/2019	53,656	12,638	11,746	14,306	N/A
3/31/2019	53,859	11,464	13,146	15,542	N/A
12/31/2018	40,825	3,824	13,691	15,827	N/A
9/30/2018	53,373	23,808	16,001	18,178	N/A
7/1/2018	53,244	22,545	N/A	17,808	N/A
4/1/2018	52,673	21,746	N/A	17,201	N/A
12/31/2017	52,546	21,305	N/A	16,802	N/A
10/1/2017	52,471	9,791	N/A	15,463	N/A
7/2/2017	52,347	8,308	N/A	15,311	N/A
4/2/2017	52,598	7,281	N/A	15,677	N/A
12/31/2016	52,824	7,198	N/A	16,192	N/A
10/2/2016	53,243	6,270	N/A	15,049	N/A
7/3/2016	52,286	7,036	N/A	15,332	N/A
4/3/2016	50,992	7,615	N/A	15,816	N/A
12/31/2015	48,851	6,948	N/A	14,688	N/A
9/27/2015	47,922	8,366	N/A	15,188	N/A
6/28/2015	48,196	8,913	N/A	14,631	N/A
3/29/2015	49,116	9,200	N/A	14,628	N/A
12/31/2014	49,605	9,085	N/A	17,084	N/A
9/28/2014	50,045	10,461	N/A	17,209	N/A
6/29/2014	50,327	10,370	N/A	18,646	N/A
3/30/2014	50,527	10,994	N/A	18,316	N/A
12/31/2013	51,584	11,339	N/A	17,684	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PFEの予測収益成長率 (年間16.8% ) は貯蓄率 ( 8.7% ) を上回っています。

収益対市場: PFEの収益 ( 16.8% ) はPE市場 ( 10.1% ) よりも速いペースで成長すると予測されています。

高成長収益: PFEの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: PFEの収益 ( 0.8% ) PE市場 ( 4% ) よりも低い成長が予測されています。

高い収益成長: PFEの収益 ( 0.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PFEの自己資本利益率は、3年後には低くなると予測されています ( 17 %)。

Pfizer 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Pfizer Inc. Announces Executive Changes

Pfizer Reportedly Explore Sale of Hospital Drugs Unit

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Upcoming dividend of US$0.42 per share

Third quarter 2024 earnings released: EPS: US$0.79 (vs US$0.42 loss in 3Q 2023)

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Pfizer Inc. Announces Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

Second quarter dividend of US$0.42 announced

U.S. FDA Approves Pfizer Inc.’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer Inc. Announces Positive Topline Results from the Final Prespecified Overall Survival Analysis of the TALAPRO-2 Study of TALZENNA®

Starboard Value Wants Pfizer to Make Changes to Turn its Performance Around

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Pfizer Inc. to Report Q3, 2024 Results on Oct 29, 2024

Pfizer Announces its BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Pfizer Inc. Launches PfizerForAll

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Pfizer Inc Announces Results of ABRYSVO® for RSV in Immunocompromised Adults

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘